Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-06-07
1998-06-02
Jarvis, William R. A.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514423, 5142232, 5142235, 514471, 514175, A61K 3140, A61K 3154, A61K 3134, A61K 31585
Patent
active
057600694
ABSTRACT:
A method of treatment using a compound of Formula I: ##STR1## wherein: R.sub.1 is hydrogen, lower alkanoyl of up to 6 carbon atoms or aroyl selected from benzoyl and naphthoyl;
REFERENCES:
patent: 4888179 (1989-12-01), Appelgren et al.
patent: 5308862 (1994-05-01), Ohlstein
patent: 5312828 (1994-05-01), Finkelstein et al.
J. of Cardiovascular Pharm; Senior, et al., "Effects of Carvedilol on Ventricular Arrhythmias", 1992, vol. 19, (Suppl. 1): pp. S117-S121.
J. of Cardiovascular Pharm; DasGupta, et al., "The Effects of Intravenous Caredilol, A New Multiple Action Vasodilatory .beta.-Blocker, in Cogestive Heart Failure", 1991, vol. 18, (Suppl. 1): pp. S12-S16.
British J. of Urology; Caine, et al., "The Use of Alpha-adrenergic Blockers in Benign Prostatic Obstruction", 1976, vol. 48, pp. 255-263.
British J. of Urology; H.N. Whitfield, et al., "The Effect of Adrenergic Blocking Drugs on Outflow Resistance", 1976, vol. 47, pp. 823-827.
American J. of Cardiology; DasGupta, et al., "Value of Carvedilol in Congestive Heart Failure Secondary to Coronary Artery Disease", 1990, vol. 66, pp. 1118-1123.
Z. Kardiol; A. Buchwald, et al., "Acute Hemodynamic Effects of the Beta-blocker Carvedilol in Heart Failure", 1990, vol. 79, No. 6, pp. 424-428.
JACC; DiLenarda, et al., "Acute Hemodynamic Effects of Carvedilol Versus Metoprolol In Idiopathic Dilated Cardiomyopathy", 1991, vol. 17, No. 2, Abstract 142A.
Frontiers in CHF; D. Tepper, "Multicenter Oral Carvedilol Heart Failure Assessment", 1996, vol. 2, No. 1, pp. 39-40.
J. of Cardiovascular Pharm; DasGupta, et al., 1990, vol. 19, (Suppl. 1): pp. 562-567.
J. of Hypertension, C. Rosendorff, "Beta-blocking agents with vasodilator activity", 1993, vol. 11, (Suppl. 4): pp. S37-S40.
Cardiology; J. Lessem, et al., "Development of a Multication Beta-blocker", 1993, vol. 82, (Suppl. 3): pp. 50-58.
Drug Safety; W.J. Louis, et al., "A Risk-Benefit Assessment of Carvedilol in the Treatment of Cardiovascular Disorders,", 1994, vol. 11, No. 2, pp. 86-93.
Drugs; McTavish, et al., "Carvedilol--A Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therepeutic Efficacy", 1993, vol. 45, No. 2, pp. 232-258.
Circulation; H. Krum, et al., "Effects of Cavedilol, a Vasodilator-.beta.-Blocker, in Patients with Congestive Heart Failure Due to Ischemic Heart Disease", 1995, vol. 92, No. 2, pp. 212-218.
CBS-TV; CBS Evenings News, Transcript, Jan. 27, 1993, 6:30-7:00pm.
CNBC; Steals and Deals, Transcript, Jan. 29, 1993, 8:30pm.
Circulation, DasGupta, et al., 1989, vol. 80, No. 4, (Suppl. II): pp. 116-117.
Drugs of Today; Ruffolo, et al., "Carvedilol (Kredex): A Novel Multiple Action Cadiovascular Agent", 1991, vol. 27, No. 7, pp. 465-492.
Lukas-Laskey Mary Ann
Ruffolo, Jr. Robert
Shusterman Neil Howard
Sponer Gisbert
Strein Klaus
Boehringer Mannheim Pharmaceuticals Corporation-SmithKline Beech
Jarvis William R. A.
Lentz Edward T.
McCarthy Mary E.
Venetianer Stephen
LandOfFree
Method of treatment for decreasing mortality resulting from cong does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treatment for decreasing mortality resulting from cong, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treatment for decreasing mortality resulting from cong will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1460262